Inclisiran sodium 300 mg

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Atherosclerotic Cardiovascular DiseaseCoronary Artery Disease

Phase 3

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruitingNCT05030428

Novartis PharmaceuticalsAtherosclerotic Cardiovascular Disease

Start: 2021-11-23End: 2027-05-10Updated: 2026-08-25

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruitingNCT05360446

Novartis PharmaceuticalsCoronary Artery Disease

Start: 2022-07-08End: 2026-10-26Updated: 2026-07-13

Related Papers

Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial

American Heart Journal2025-08-052 citations

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial

Circulation2025-05-207 citations

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Cardiovascular Research2024-05-1565 citations

Impact of Platelet-to-HDL-Cholesterol Ratio on Long-Term Mortality in Coronary Artery Disease Patients with or Without Type 2 Diabetes: Insights from a Chinese Multicenter Cohort

Journal of Inflammation Research2024-05-0111 citations

Efficacy and Safety of Inclisiran in Asian Patients

JACC Asia2023-11-1421 citations